JP2007509143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509143A5 JP2007509143A5 JP2006536635A JP2006536635A JP2007509143A5 JP 2007509143 A5 JP2007509143 A5 JP 2007509143A5 JP 2006536635 A JP2006536635 A JP 2006536635A JP 2006536635 A JP2006536635 A JP 2006536635A JP 2007509143 A5 JP2007509143 A5 JP 2007509143A5
- Authority
- JP
- Japan
- Prior art keywords
- pyridin
- methanone
- chlorophenyl
- bistrifluoromethylbenzyl
- triazol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 3,5-bistrifluoromethylbenzyl Chemical group 0.000 claims 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 7
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000000068 chlorophenyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 3
- GMNRLJOAZMNQMK-UHFFFAOYSA-N (2-chlorophenyl)-[2-(2-hydroxy-2-pyridin-4-ylethenyl)pyridin-3-yl]methanone Chemical compound C=1C=NC=CC=1C(O)=CC1=NC=CC=C1C(=O)C1=CC=CC=C1Cl GMNRLJOAZMNQMK-UHFFFAOYSA-N 0.000 claims 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- JKGHUBCPWOLOFQ-UHFFFAOYSA-N 1-(azidomethyl)-3,5-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(CN=[N+]=[N-])=CC(C(F)(F)F)=C1 JKGHUBCPWOLOFQ-UHFFFAOYSA-N 0.000 claims 1
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 235000021355 Stearic acid Nutrition 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000008117 stearic acid Substances 0.000 claims 1
- 229960004274 stearic acid Drugs 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51430003P | 2003-10-24 | 2003-10-24 | |
| US60/514,300 | 2003-10-24 | ||
| PCT/US2004/030914 WO2005042515A1 (en) | 2003-10-24 | 2004-10-12 | Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509143A JP2007509143A (ja) | 2007-04-12 |
| JP2007509143A5 true JP2007509143A5 (https=) | 2007-10-18 |
| JP4959336B2 JP4959336B2 (ja) | 2012-06-20 |
Family
ID=34549327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536635A Expired - Lifetime JP4959336B2 (ja) | 2003-10-24 | 2004-10-12 | ｛２−［１−（３，５−ビストリフルオロメチルベンジル）−５−ピリジン−４−イル−１ｈ−［１，２，３］トリアゾル−４−イル］−ピリジン−３−イル｝−（２−クロロフェニル）−メタノンの新規の結晶形態 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7381826B2 (https=) |
| JP (1) | JP4959336B2 (https=) |
| KR (1) | KR100848407B1 (https=) |
| CN (1) | CN1863791B (https=) |
| AR (1) | AR046131A1 (https=) |
| AT (1) | ATE462700T1 (https=) |
| AU (1) | AU2004285855B8 (https=) |
| BR (1) | BRPI0415010B8 (https=) |
| CA (1) | CA2542140C (https=) |
| CL (2) | CL2009001311A1 (https=) |
| CR (1) | CR8353A (https=) |
| DE (1) | DE602004026333D1 (https=) |
| DK (1) | DK1675846T3 (https=) |
| EA (1) | EA008881B1 (https=) |
| EC (1) | ECSP066517A (https=) |
| ES (1) | ES2340772T3 (https=) |
| HR (1) | HRP20100207T1 (https=) |
| IL (1) | IL174926A0 (https=) |
| MA (1) | MA28329A1 (https=) |
| MY (1) | MY157375A (https=) |
| NO (1) | NO335090B1 (https=) |
| NZ (2) | NZ545917A (https=) |
| PE (1) | PE20050481A1 (https=) |
| PT (1) | PT1675846E (https=) |
| TW (1) | TW200524906A (https=) |
| UA (1) | UA82901C2 (https=) |
| WO (1) | WO2005042515A1 (https=) |
| ZA (1) | ZA200603234B (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0721069A2 (pt) | 2006-12-20 | 2014-02-04 | Lilly Co Eli | Intermediários e processo útil na preparação de {2-[1-(3,5-bis-trifluorometil-benzil)-5-piridin-4-il-1h[1,2, 3]triazol-4-il]-piridin-3-il}-2-clorofenil)-metanona |
| WO2009075778A2 (en) * | 2007-12-06 | 2009-06-18 | The Regents Of The University Of California | Nonpeptidic inhibitors of cruzain |
| US8080568B1 (en) * | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| ES2824552T3 (es) | 2015-03-04 | 2021-05-12 | Vanda Pharmaceuticals Inc | Método de tratamiento con tradipitant |
| WO2017031215A1 (en) * | 2015-08-17 | 2017-02-23 | Eli Lilly And Company | Process development of a pyridine-containing nk-1 receptor antagonist |
| AU2018331267B2 (en) | 2017-09-13 | 2024-03-07 | Vanda Pharmaceuticals Inc. | Improved treatment of atopic dermatitis with tradipitant |
| CN119074729A (zh) * | 2017-11-17 | 2024-12-06 | 万达制药公司 | 使用川地匹坦治疗胃肠疾病的方法 |
| CA3101210A1 (en) * | 2018-06-08 | 2019-12-12 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| US10821099B2 (en) | 2018-09-28 | 2020-11-03 | Vanda Pharmaceuticals Inc. | Use of tradipitant in motion sickness |
| HUE070000T2 (hu) | 2018-09-28 | 2025-04-28 | Vanda Pharmaceuticals Inc | Tradipitant alkalmazása utazási betegségben |
| WO2020117811A1 (en) * | 2018-12-03 | 2020-06-11 | Vanda Pharmaceuticals Inc. | Method of treatment with tradipitant |
| KR20220145844A (ko) | 2020-02-25 | 2022-10-31 | 반다 파마슈티칼즈, 인코퍼레이티드. | 트라디피탄트를 이용한 아토피 피부염의 개선된 치료 |
| JP7791832B2 (ja) | 2020-03-26 | 2025-12-24 | バンダ・ファーマシューティカルズ・インコーポレイテッド | トラジピタントによる下気道感染症の治療 |
| WO2023019084A1 (en) | 2021-08-12 | 2023-02-16 | Vanda Pharmaceuticals Inc. | Treatment of gastric accommodation with tradipitant |
| US20240350469A1 (en) | 2021-08-31 | 2024-10-24 | Vanda Pharmaceuticals Inc. | Treatment of lower respiratory tract infection with tradipitant |
| AU2023413130A1 (en) | 2022-12-21 | 2025-06-05 | Vanda Pharmaceuticals Inc. | Methods of treatment with tradipitant |
| EP4599831A1 (en) | 2024-02-09 | 2025-08-13 | Vanda Pharmaceuticals Inc. | Treatment of gastroparesis with tradipitant |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020099067A1 (en) * | 1993-07-08 | 2002-07-25 | Ulrich Posanski | Pharmaceutical compositions for sparingly soluble therapeutic agents |
| GB9505492D0 (en) * | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
| GB9525296D0 (en) * | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
| DE69736390T2 (de) * | 1996-10-07 | 2007-07-26 | Merck Sharp & Dohme Ltd., Hoddesdon | Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum |
| BR0013551A (pt) * | 1999-08-13 | 2003-06-17 | Vertex Pharma | Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas |
| AU1343901A (en) * | 1999-10-29 | 2001-05-14 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
| US20020044971A1 (en) * | 2000-07-07 | 2002-04-18 | Amidon Gordon L. | Dissolution rate of poorly soluble drugs |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
-
2004
- 2004-10-12 BR BRPI0415010A patent/BRPI0415010B8/pt not_active IP Right Cessation
- 2004-10-12 CN CN2004800291393A patent/CN1863791B/zh not_active Expired - Lifetime
- 2004-10-12 PT PT04793893T patent/PT1675846E/pt unknown
- 2004-10-12 AU AU2004285855A patent/AU2004285855B8/en not_active Expired
- 2004-10-12 DE DE602004026333T patent/DE602004026333D1/de not_active Expired - Lifetime
- 2004-10-12 ES ES04793893T patent/ES2340772T3/es not_active Expired - Lifetime
- 2004-10-12 WO PCT/US2004/030914 patent/WO2005042515A1/en not_active Ceased
- 2004-10-12 KR KR1020067007751A patent/KR100848407B1/ko not_active Expired - Lifetime
- 2004-10-12 NZ NZ545917A patent/NZ545917A/en unknown
- 2004-10-12 US US10/574,712 patent/US7381826B2/en not_active Expired - Lifetime
- 2004-10-12 CA CA2542140A patent/CA2542140C/en not_active Expired - Lifetime
- 2004-10-12 NZ NZ580480A patent/NZ580480A/en unknown
- 2004-10-12 EA EA200600829A patent/EA008881B1/ru not_active IP Right Cessation
- 2004-10-12 DK DK04793893.1T patent/DK1675846T3/da active
- 2004-10-12 AT AT04793893T patent/ATE462700T1/de active
- 2004-10-12 HR HR20100207T patent/HRP20100207T1/hr unknown
- 2004-10-12 JP JP2006536635A patent/JP4959336B2/ja not_active Expired - Lifetime
- 2004-10-20 AR ARP040103801A patent/AR046131A1/es not_active Application Discontinuation
- 2004-10-20 PE PE2004001008A patent/PE20050481A1/es not_active Application Discontinuation
- 2004-10-21 MY MYPI20044338A patent/MY157375A/en unknown
- 2004-10-22 TW TW093132097A patent/TW200524906A/zh unknown
- 2004-12-10 UA UAA200604473A patent/UA82901C2/uk unknown
-
2006
- 2006-04-11 IL IL174926A patent/IL174926A0/en unknown
- 2006-04-21 CR CR8353A patent/CR8353A/es not_active Application Discontinuation
- 2006-04-21 ZA ZA200603234A patent/ZA200603234B/en unknown
- 2006-04-21 EC EC2006006517A patent/ECSP066517A/es unknown
- 2006-05-22 MA MA29043A patent/MA28329A1/fr unknown
- 2006-05-24 NO NO20062371A patent/NO335090B1/no unknown
-
2009
- 2009-05-29 CL CL2009001311A patent/CL2009001311A1/es unknown
- 2009-05-29 CL CL2009001310A patent/CL2009001310A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509143A5 (https=) | ||
| JP4624667B2 (ja) | １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相 | |
| JP4336106B2 (ja) | 非晶質アトルバスタチンカルシウムの調製 | |
| BG64508B1 (bg) | Кристален полиморфен (+)-(s)- клопидогрел хидрогенсулфат, метод за получаването му и фармацевтичен състав, който го съдържа | |
| JP2004501191A (ja) | カルベジロール | |
| JP2007504160A5 (https=) | ||
| CA3097312A1 (en) | Crystalline forms of a tlr7/tlr8 inhibitor | |
| JP2002509136A (ja) | Ｈｉｖプロテアーゼ抑制剤重硫酸塩 | |
| JP2006514626A5 (https=) | ||
| RU2000128658A (ru) | Тиенилазолилалкоксиэтанамны, их производные и их применение в качестве лекарственных средств | |
| SG184721A1 (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| JP2023548160A (ja) | １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物 | |
| CA2542140A1 (en) | Crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone | |
| CN104098570A (zh) | 替卡格雷晶型及其制备方法和用途 | |
| JP2024517431A5 (https=) | ||
| TWI445697B (zh) | 塔適那偉（ａｔａｚａｎａｖｉｒ）硫酸氫鹽之製法及其新穎的形式 | |
| RU2193560C2 (ru) | Новая соль | |
| CA2518999A1 (en) | Crystalline and amorphous solids of pantoprazole and processes for their preparation | |
| HUP0300596A2 (hu) | Amorf toraszemid módosulat, eljárás az előállítására, alkalmazása és ezt tartalmazó gyógyszerkészítmények | |
| JP2018521055A (ja) | サクビトリルカルシウム塩 | |
| JP2016539994A (ja) | α，ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法 | |
| HUP0302135A2 (hu) | A toraszemid új V. polimorf módosulata, eljárás előállítására, alkalmazása nyersanyagként, valamint ilyen módosulatot tartalmazó gyógyászati készítmények | |
| TWI819279B (zh) | 2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸之鉀鹽 | |
| JP2007528349A (ja) | 高い安定性を有する無定形アムロジピンカムシレート、その製造方法及びこれを含む経口投与用組成物 | |
| CN115581118A (zh) | 制造结晶形式的2-[(4s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-4h-喹唑啉-4-基]乙酸钠三水合物的方法 |